Navigation Links
St. Jude Children's Research Hospital announces issuance of US patent for cancer therapy
Date:3/19/2013

The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for St. Jude's invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults.

"This groundbreaking invention enables human immune cells to recognize and attack certain cells that cause leukemia and lymphoma, cancers of the blood and lymphatic tissue," said James R. Downing, M.D., St. Jude scientific director.

The patented technology represents a potentially potent new therapeutic weapon against such diseases as B-cell acute lymphoblastic leukemia (ALL), B-cell chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL). Each year approximately 71,650 people in the United States are diagnosed with these diseases.

The invention involves genetically modifying human immune cells to enable them to manufacture a large protein molecule called a "chimeric antigen receptor" (CAR). The protein molecule is "chimeric" in that it is made from parts that do not exist together in the same molecule in nature. It is a "receptor" because a portion of it extends outside the surface of the immune cell and can receive signals from external "antigens." An antigen is a substance capable of stimulating an immune response in the human body. The CAR invented by St. Jude fits and latches onto "CD19" antigens prevalent on the B cells that cause ALL, CLL and NHL. It then stimulates the human immune cell to attack and kill the B cells.

"This exciting invention provides a new and promising treatment option for children and adults with these life-threatening diseases and sets the stage for treating other forms of cancer with cellular immunotherapy," Downing said.

In view of the landmark nature of the patent and the extraordinary potential of the technology for widespread use, St. Jude will make the technology available for license.


'/>"/>

Contact: Summer Freeman
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. Diabetes Research Institute develops oxygen-generating biomaterial
4. APS issues new policy requiring identification of sex or gender in reporting scientific research
5. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
6. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
7. U of Alberta researcher steps closer to understand autoimmune diseases
8. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
9. A project to research biological and chemical aspects of microalgae to fuel approach
10. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
11. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/17/2016)... OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has ... using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer storage ... ... ... Setting up ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... McLean, VA (PRWEB) , ... December 07, 2016 ... ... peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced ... Further refinement in defining the optimal patient population and timing of blood sampling ...
(Date:12/7/2016)... LANSING, Mich. , Dec. 7, 2016 ... it has named Dr. Dan Kephart as ... the company. Kephart will assume his responsibilities at Neogen ... research and development director for the agribusiness unit of ... food safety development at Life Technologies. His extensive industry ...
Breaking Biology Technology: